LABTLakewood-Amedex Biotherapeutics Inc.vs its industry peers
A metric-by-metric comparison of Lakewood-Amedex Biotherapeutics Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LABT본 종목 | $5M#9 | — | 1.1x#10 | — | — | 20.8%#12 | — | -88.8%#4 | — | — | — | — |
| SYBX | $7M#2 | — | 0.6x#7 | — | -100.0%#8 | 95.7%#2 | — | -8.4%#1 | — | — | -63.8%#6 | — |
| BOLT | $7M#3 | — | 0.5x#6 | 0.9x#2 | 0.1%#5 | 47.1%#6 | -469.3%#5 | -264.1%#11 | — | — | -30.3%#3 | — |
| XBIO | $6M#4 | — | 1.1x#9 | 2.2x#5 | 19.0%#2 | 32.3%#11 | -95.2%#2 | -44.1%#2 | -1516.8%#6 | 4#1 | -15.2%#2 | — |
| ERNA | $6M#5 | 0.1x#3 | 2.0x#12 | 10.8x#6 | 755.9%#1 | 68.4%#5 | -1601.2%#6 | -440.1%#13 | -1016.2%#5 | — | -88.1%#10 | — |
| PCSA | $5M#7 | 3.0x#4 | — | — | — | 214.5%#1 | — | — | — | — | -61.7%#5 | 0.8%#1 |
| PULM | $5M#8 | — | 2.0x#13 | 0.7x#1 | 7.0%#4 | 46.0%#7 | -66.2%#1 | -201.9%#8 | -235.7%#2 | — | -71.4%#7 | — |
| PRPH | $6M#6 | — | — | 1.3x#3 | -35.8%#6 | 72.4%#4 | -415.4%#4 | — | -804.6%#4 | — | -91.4%#11 | — |
| DRMA | $5M#10 | — | 1.3x#11 | — | — | 38.5%#9 | — | -216.7%#10 | — | — | -78.6%#8 | — |
| RVPH | $5M#11 | — | 0.3x#1 | — | — | 33.6%#10 | — | -130.6%#7 | — | — | -95.7%#14 | — |
| INM | $8M#1 | — | 7.2x#14 | 1.6x#4 | 7.5%#3 | -53.9%#16 | -160.8%#3 | -1168.4%#14 | — | — | -40.7%#4 | — |
| GRI | $4M#12 | — | 0.4x#4 | — | -100.0%#8 | -45.7%#15 | — | -116.3%#6 | — | — | -96.4%#15 | — |
| CVKD | $4M#13 | — | 1.0x#8 | — | — | -24.3%#13 | — | -323.5%#12 | -585.1%#3 | — | -91.6%#12 | — |
| REVB | $4M#14 | 0.0x#1 | 0.4x#3 | — | — | 40.7%#8 | — | -88.5%#3 | — | — | -84.4%#9 | — |
| BIVIW | $4M#15 | — | 0.4x#2 | — | — | -25.8%#14 | — | -214.9%#9 | -1671.2%#7 | — | -7.7%#1 | — |
| HCWB | $3M#16 | 0.1x#2 | 0.5x#5 | 64.3x#7 | -97.9%#7 | 73.5%#3 | -24270.7%#7 | -107.2%#5 | -99.4%#1 | 3#2 | -93.0%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice